NO314924B1 - Farmasöytisk preparat omfattende rapamycin eller et derivat derav samt fremgangsmåte for fremstilling derav - Google Patents
Farmasöytisk preparat omfattende rapamycin eller et derivat derav samt fremgangsmåte for fremstilling derav Download PDFInfo
- Publication number
- NO314924B1 NO314924B1 NO19980081A NO980081A NO314924B1 NO 314924 B1 NO314924 B1 NO 314924B1 NO 19980081 A NO19980081 A NO 19980081A NO 980081 A NO980081 A NO 980081A NO 314924 B1 NO314924 B1 NO 314924B1
- Authority
- NO
- Norway
- Prior art keywords
- rapamycin
- pharmaceutical preparation
- solid dispersion
- derivative
- preparation according
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 63
- 229960002930 sirolimus Drugs 0.000 title claims abstract description 56
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 4
- 238000002360 preparation method Methods 0.000 title claims description 37
- 238000000034 method Methods 0.000 title claims description 9
- 239000007962 solid dispersion Substances 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 15
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 5
- 229920003169 water-soluble polymer Polymers 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- QFMKPDZCOKCBAQ-NFCVMBANSA-N sar943-nxa Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)CC1 QFMKPDZCOKCBAQ-NFCVMBANSA-N 0.000 claims description 3
- 239000002609 medium Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 229920000858 Cyclodextrin Polymers 0.000 description 10
- -1 amide esters Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000036457 multidrug resistance Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012907 medicinal substance Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000004945 acylaminoalkyl group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000956 methoxy group Chemical class [H]C([H])([H])O* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- CFZGEMKIQUVTCC-UHFFFAOYSA-N octacos-18-ene-2,3,10,16-tetrone Chemical compound CCCCCCCCCC=CCC(=O)CCCCCC(=O)CCCCCCC(=O)C(C)=O CFZGEMKIQUVTCC-UHFFFAOYSA-N 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9514397.0A GB9514397D0 (en) | 1995-07-14 | 1995-07-14 | Organic compounds |
| GBGB9515025.6A GB9515025D0 (en) | 1995-07-21 | 1995-07-21 | Organic compounds |
| PCT/EP1996/003066 WO1997003654A2 (en) | 1995-07-14 | 1996-07-12 | Pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO980081L NO980081L (no) | 1998-01-08 |
| NO980081D0 NO980081D0 (no) | 1998-01-08 |
| NO314924B1 true NO314924B1 (no) | 2003-06-16 |
Family
ID=26307397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19980081A NO314924B1 (no) | 1995-07-14 | 1998-01-08 | Farmasöytisk preparat omfattende rapamycin eller et derivat derav samt fremgangsmåte for fremstilling derav |
| NO20025089A NO317702B1 (no) | 1995-07-14 | 2002-10-23 | Farmasoytiske preparater |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025089A NO317702B1 (no) | 1995-07-14 | 2002-10-23 | Farmasoytiske preparater |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US6004973A (hu) |
| EP (2) | EP0839028B1 (hu) |
| JP (4) | JPH11509223A (hu) |
| KR (1) | KR100352943B1 (hu) |
| CN (1) | CN1080120C (hu) |
| AT (2) | ATE310519T1 (hu) |
| AU (1) | AU706174B2 (hu) |
| BE (1) | BE1009856A5 (hu) |
| BR (1) | BR9609537A (hu) |
| CA (2) | CA2426956C (hu) |
| CL (1) | CL2003002715A1 (hu) |
| CY (2) | CY2603B2 (hu) |
| CZ (1) | CZ291305B6 (hu) |
| DE (2) | DE69635499T2 (hu) |
| DK (2) | DK1281400T3 (hu) |
| ES (2) | ES2250566T3 (hu) |
| FR (1) | FR2736550B1 (hu) |
| HK (1) | HK1016081A1 (hu) |
| HU (1) | HU226774B1 (hu) |
| IL (2) | IL144684A (hu) |
| IT (1) | IT1284871B1 (hu) |
| NO (2) | NO314924B1 (hu) |
| NZ (1) | NZ313633A (hu) |
| PL (1) | PL191933B1 (hu) |
| PT (1) | PT839028E (hu) |
| RU (1) | RU2159107C2 (hu) |
| SI (2) | SI1281400T1 (hu) |
| SK (2) | SK283571B6 (hu) |
| TR (1) | TR199800045T1 (hu) |
| UY (1) | UY25896A1 (hu) |
| WO (1) | WO1997003654A2 (hu) |
Families Citing this family (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| CA2230748C (en) * | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
| RU2214244C9 (ru) * | 1998-03-26 | 2020-07-29 | Астеллас Фарма Инк. | Препараты с замедленным высвобождением |
| JP3718341B2 (ja) | 1998-05-12 | 2005-11-24 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロースとその製造方法 |
| US20060240070A1 (en) * | 1998-09-24 | 2006-10-26 | Cromack Keith R | Delivery of highly lipophilic agents via medical devices |
| GB9826882D0 (en) | 1998-12-07 | 1999-01-27 | Novartis Ag | Organic compounds |
| AU2003200370B2 (en) * | 1998-12-07 | 2005-10-27 | Novartis Ag | Stabilization of macrolides |
| AU4565000A (en) | 1999-05-10 | 2000-11-21 | Novartis Ag | Organic compounds |
| EP1054019A1 (en) * | 1999-05-18 | 2000-11-22 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose |
| US6593292B1 (en) | 1999-08-24 | 2003-07-15 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
| US6680069B1 (en) | 1999-11-09 | 2004-01-20 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose and process for manufacturing the same |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| JP5767429B2 (ja) | 1999-11-12 | 2015-08-19 | アッヴィ・インコーポレイテッド | 固体分散剤中の結晶化阻害剤 |
| JP3552160B2 (ja) | 2000-01-14 | 2004-08-11 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロース粒子の形成方法 |
| IL134701A0 (en) * | 2000-02-23 | 2001-04-30 | J P M E D Ltd | Homogeneous solid matrix containing vegetable proteins |
| DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
| BR0209474A (pt) * | 2001-05-09 | 2006-02-07 | Novartis Ag | Métodos para imunomodulação seletiva |
| US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
| US20040137066A1 (en) * | 2001-11-26 | 2004-07-15 | Swaminathan Jayaraman | Rationally designed therapeutic intravascular implant coating |
| GB0123400D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| AU2006218279B2 (en) * | 2001-09-28 | 2009-12-10 | Novartis Ag | Pharmaceutical compositions comprising colloidal silicon dioxide |
| US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| US7682387B2 (en) | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| EP1469832B2 (en) * | 2002-02-01 | 2016-10-26 | Bend Research, Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
| KR20040079967A (ko) * | 2002-02-01 | 2004-09-16 | 화이자 프로덕츠 인크. | 고체 약물 분산액을 함유하는 속방형 제형 |
| PL216224B1 (pl) | 2002-02-01 | 2014-03-31 | Ariad Pharmaceuticals | Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie |
| JP3956114B2 (ja) * | 2002-06-28 | 2007-08-08 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 表示制御方法、これを用いたプログラム、情報処理装置及び光学式文字読み取り装置 |
| PL376169A1 (en) * | 2002-11-15 | 2005-12-27 | Novartis Ag | Drug delivery system |
| AR043504A1 (es) * | 2003-03-17 | 2005-08-03 | Novartis Ag | Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias |
| US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
| US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
| WO2005004848A1 (en) * | 2003-07-09 | 2005-01-20 | Chong Kun Dang Pharmaceutical Corp. | The solid dispersion of tacrolimus |
| CA2532931A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| JP2007504226A (ja) * | 2003-09-03 | 2007-03-01 | ワイス | 非晶質状のラパマイシンの３−ヒドロキシ−２−（ヒドロキシメチル）−２−メチルプロピオン酸との４２−エステル、およびそれを含むその医薬組成物 |
| CA2539324A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| US7780973B2 (en) * | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
| US20050142161A1 (en) * | 2003-12-30 | 2005-06-30 | Freeman Lynetta J. | Collagen matrix for soft tissue augmentation |
| ES2298861T3 (es) * | 2004-01-08 | 2008-05-16 | Wyeth | Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779. |
| EP1710244A4 (en) | 2004-01-29 | 2009-06-17 | Eisai R&D Man Co Ltd | METHOD FOR STABILIZING A MACROLIDE COVERAGE |
| RU2006141358A (ru) | 2004-04-23 | 2008-05-27 | Сайдекс, Инк. (Us) | Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина |
| JP5117190B2 (ja) | 2004-08-27 | 2013-01-09 | コーディス・コーポレイション | 溶媒を含有しない非晶質ラパマイシン |
| MX2007003731A (es) * | 2004-09-29 | 2007-08-14 | Johnson & Johnson | Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables. |
| US20060088591A1 (en) * | 2004-10-22 | 2006-04-27 | Jinghua Yuan | Tablets from a poorly compressible substance |
| KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
| US8637070B2 (en) | 2005-02-09 | 2014-01-28 | Santen Pharmaceutical Co., Ltd. | Rapamycin formulations and methods of their use |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| JP2008532953A (ja) * | 2005-03-08 | 2008-08-21 | ライフサイクル ファーマ エー／エス | シロリムスおよび／またはその類縁物質を含む医薬組成物 |
| EP1868663B1 (en) * | 2005-03-23 | 2011-11-16 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| US20060240108A1 (en) * | 2005-04-26 | 2006-10-26 | Bernard Bobby L | Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability |
| DE102005026755A1 (de) * | 2005-06-09 | 2006-12-14 | Basf Ag | Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| EA015922B1 (ru) | 2005-11-14 | 2011-12-30 | Ариад Фармасьютикалз, Инк. | ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ |
| US7700614B2 (en) | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
| EP2001438A2 (en) | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
| US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
| EP1938800A1 (en) | 2006-12-06 | 2008-07-02 | Ranbaxy Laboratories Limited | Sirolimus nanodispersion |
| WO2008082982A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Improved assay for immunosuppressant drugs |
| EP2118654B1 (en) | 2006-12-29 | 2013-03-27 | Abbott Laboratories | Diagnostic test for the detection of a molecule or drug in whole blood |
| WO2008082984A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Non-denaturing lysis reagent for use with capture-in-solution immunoassay |
| US7914999B2 (en) | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
| EP1952807A1 (en) * | 2007-01-24 | 2008-08-06 | LEK Pharmaceuticals D.D. | Sirolimus formulation |
| CN107080734B (zh) | 2008-03-20 | 2020-10-30 | 维尔恩公司 | 包含生育酚的peg衍生物的乳剂 |
| SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
| PT2365802T (pt) | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
| FR2943539B1 (fr) | 2009-03-31 | 2011-07-22 | Ethypharm Sa | Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus. |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| SG181916A1 (en) * | 2009-12-22 | 2012-08-30 | Abbott Lab | Abt-263 capsule |
| KR101622441B1 (ko) | 2010-03-23 | 2016-05-18 | 버런, 아이엔씨. | 자당 지방산 에스테르를 포함하는 나노에멀전 |
| KR101620661B1 (ko) | 2010-04-27 | 2016-05-12 | 로슈 글리카트 아게 | 어푸코실화된 ＣＤ20 항체와 mTOR 억제제의 복합 요법 |
| IT1400977B1 (it) | 2010-07-01 | 2013-07-05 | Euticals Spa | Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine. |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| MY191300A (en) | 2010-11-23 | 2022-06-14 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| JP6141188B2 (ja) | 2010-11-23 | 2017-06-07 | アッヴィ・インコーポレイテッド | アポトーシス誘導剤の塩および結晶の形態 |
| WO2012092421A2 (en) * | 2010-12-30 | 2012-07-05 | Surmodics, Inc. | Composition for intravascular delivery of therapeutic composition |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| US20120303115A1 (en) * | 2011-05-25 | 2012-11-29 | Dadino Ronald C | Expandable devices coated with a rapamycin composition |
| US8809562B2 (en) | 2011-06-06 | 2014-08-19 | Chevron Phillips Chemical Company Lp | Use of metallocene compounds for cancer treatment |
| WO2013022201A1 (en) * | 2011-08-11 | 2013-02-14 | Dong-A Pharm. Co., Ltd. | Process of preparing a stabilized and solubilized formulation of sirolimus derivatives |
| KR101151890B1 (ko) * | 2011-08-11 | 2012-05-31 | 동아제약주식회사 | 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법 |
| AU2012320563B2 (en) | 2011-10-06 | 2016-05-12 | Novartis Ag | Pharmaceutical compositions comprising 40 - O - ( 2 - hydroxy) ethyl - rapamycin |
| EP2594260A1 (en) * | 2011-11-18 | 2013-05-22 | LEK Pharmaceuticals d.d. | Solid preparations comprising sirolimus with desired bioavailability and method for its preparation |
| US8912215B2 (en) * | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
| KR200477251Y1 (ko) * | 2011-12-30 | 2015-05-22 | 엘에스산전 주식회사 | 배선용 차단기의 주 접점 위치 표시 기구 |
| CN103585122B (zh) * | 2012-08-17 | 2017-12-05 | 山东新时代药业有限公司 | 一种含依维莫司的片剂及其制备方法 |
| US20150290176A1 (en) | 2012-10-12 | 2015-10-15 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| US9610385B2 (en) * | 2013-03-07 | 2017-04-04 | Abbott Cardiovascular Systems Inc. | Method of fabricating an implantable medical device comprising a rapamycin derivative |
| WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TW201503912A (zh) | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| CN113768881A (zh) | 2013-10-08 | 2021-12-10 | 人工智能治疗公司 | 用于治疗淋巴管平滑肌瘤病的雷帕霉素 |
| US20150140036A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Institutes For Biomedical Research, Inc. | Low, immune enhancing, dose mtor inhibitors and uses thereof |
| CN103610646B (zh) * | 2013-12-05 | 2015-07-15 | 江苏奥赛康药业股份有限公司 | 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂 |
| CN116478927A (zh) | 2013-12-19 | 2023-07-25 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| CN104721158B (zh) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
| EP3089737B1 (en) | 2013-12-31 | 2021-11-03 | Rapamycin Holdings, LLC | Oral rapamycin nanoparticle preparations and use |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| KR20160120739A (ko) | 2014-02-11 | 2016-10-18 | 램 테라퓨틱스, 인코포레이티드 | 림프관평활근종증의 치료를 위한 라파마이신 |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| AU2015237200A1 (en) | 2014-03-27 | 2016-10-06 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
| RU2718583C2 (ru) | 2014-04-04 | 2020-04-08 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Рапамицин-содержащая композиция, вводимая путем ингаляции для лечения возрастных заболеваний |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| CA2968049A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| CA2950589A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
| WO2016014576A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| RU2724999C2 (ru) | 2014-08-19 | 2020-06-29 | Новартис Аг | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей |
| WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| WO2016057712A1 (en) | 2014-10-07 | 2016-04-14 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| WO2016135740A1 (en) | 2015-02-23 | 2016-09-01 | Natco Pharma Limited | Process for preparing stable oral compositions of everolimus |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| EP3329916A4 (en) | 2015-07-28 | 2019-03-20 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME |
| EP3342410A4 (en) * | 2015-08-28 | 2019-04-24 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL COMPOSITION WITH RAPAMYCIN OR DERIVATIVES THEREOF |
| WO2017038925A1 (ja) * | 2015-09-03 | 2017-03-09 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| EP3466424A1 (en) | 2016-05-27 | 2019-04-10 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprizing rapamycin or derivative thereof |
| CA3031542A1 (en) | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
| JP6857663B2 (ja) * | 2016-10-04 | 2021-04-14 | 日本化薬株式会社 | ラパマイシン誘導体を含有する固体分散体の製造方法 |
| TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
| TW201825090A (zh) | 2016-11-23 | 2018-07-16 | 瑞士商諾華公司 | 增強免疫反應之方法 |
| CN107080738A (zh) * | 2017-04-26 | 2017-08-22 | 四川制药制剂有限公司 | 乙酰螺旋霉素片的制备方法 |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3624863B1 (en) | 2017-05-15 | 2021-04-14 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| JP7262581B2 (ja) | 2018-11-14 | 2023-04-21 | ルトニックス，インコーポレーテッド | 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス |
| CN113939324A (zh) | 2019-04-08 | 2022-01-14 | 巴德外周血管股份有限公司 | 在经改性装置表面上具有药物洗脱涂层的医疗装置 |
| EP3741367A1 (en) | 2019-05-21 | 2020-11-25 | Premark Pharma GmbH | Treatment of ocular disease |
| EP3991750A4 (en) * | 2019-06-26 | 2022-08-03 | Ricoh Company, Ltd. | PHARMACEUTICAL COMPOSITION |
| WO2021124264A1 (en) * | 2019-12-19 | 2021-06-24 | Triviumvet Dac | Veterinary formulations comprising rapamycin and methods of using the same for treating animal diseases |
| EP4370160A1 (en) | 2021-07-15 | 2024-05-22 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
| WO2024209038A1 (en) | 2023-04-06 | 2024-10-10 | Premark Pharma Gmbh | Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3852421A (en) | 1970-03-23 | 1974-12-03 | Shinetsu Chemical Co | Excipient and shaped medicaments prepared therewith |
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US4127647A (en) * | 1975-04-08 | 1978-11-28 | Meiji Seika Kaisha, Ltd. | Process for preparation of stable amorphous macrolide antibiotic solids |
| US4248856A (en) | 1979-07-10 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| JPS5620513A (en) | 1979-07-31 | 1981-02-26 | Eisai Co Ltd | Sugar-coated tablet containing fat-soluble drug |
| US4309404A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309405A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| AU543727B2 (en) | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
| FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
| US4415547A (en) | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
| US4650666A (en) | 1983-11-30 | 1987-03-17 | Dainippon Pharmaceutical Co., Ltd. | Pullulan and sugar coated pharmaceutical composition |
| US4753801A (en) | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
| US4659336A (en) | 1986-03-28 | 1987-04-21 | Texaco Inc. | Motor fuel composition |
| GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
| US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| DE3823702A1 (de) | 1988-07-13 | 1990-01-25 | Bayer Ag | Verfahren zur herstellung von acryloylgruppen enthaltenden polyestern und ihre verwendung als lackbindemittel |
| GB2222683B (en) | 1988-08-17 | 1992-04-15 | Hydramotion Ltd | Device for moisture measurement of particulate material |
| PT93772A (pt) * | 1989-04-17 | 1991-01-08 | Searle & Co | Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer |
| US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| NZ235991A (en) * | 1989-11-09 | 1993-05-26 | Sandoz Ltd | Macrolide compounds and pharmaceutical compositions thereof |
| US5352671A (en) * | 1989-11-09 | 1994-10-04 | Sandoz Ltd. | Heteroatoms-containing tricyclic compounds |
| JPH03240726A (ja) * | 1990-02-15 | 1991-10-28 | Fujisawa Pharmaceut Co Ltd | 化学療法効果増強剤 |
| US5260301A (en) | 1990-03-01 | 1993-11-09 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical solution containing FK-506 |
| JP2542122B2 (ja) | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | 球状核、球形顆粒およびその製造方法 |
| JPH05507090A (ja) | 1990-05-08 | 1993-10-14 | リポサーム テクノロジー インコーポレイテッド | 直接噴霧乾燥された薬剤／脂質粉末組成物 |
| US5135934A (en) | 1990-07-06 | 1992-08-04 | Du Pont Merck Pharmaceutical Company | 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents |
| DE69129459T2 (de) | 1990-08-10 | 1998-10-15 | Anormed Inc | Immunosuppressive zusammensetzungen |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| IL101353A0 (en) | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| AU1537292A (en) * | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| WO1992019278A1 (en) * | 1991-04-26 | 1992-11-12 | Kurume University | Use of macrolide compounds for eye diseases |
| DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
| ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5457111A (en) | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
| US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5817333A (en) | 1991-10-31 | 1998-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing a tricyclic compound |
| ATE193652T1 (de) | 1992-03-30 | 2000-06-15 | American Home Prod | Rapamycin formulierung zur iv-injektion |
| KR100284210B1 (ko) | 1992-04-28 | 2001-03-02 | 이건 이. 버그 | 과증식성 혈관 질환 치료용 배합 제제 |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5315246A (en) | 1992-08-19 | 1994-05-24 | Eastman Kodak Company | Rotating source for generating a magnetic field for use with a currency detector |
| GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5457194A (en) | 1993-03-17 | 1995-10-10 | Abbott Laboratories | Substituted aliphatic amine-containing macrocyclic immunomodulators |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| GB2278780B (en) | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
| GB2279006A (en) * | 1993-06-03 | 1994-12-21 | Fujisawa Pharmaceutical Co | Treatment of amyotrophic lateral sclerosis |
| US5352783A (en) | 1993-06-09 | 1994-10-04 | Merck & Co., Inc. | Microbial transformation product having immunosuppressive activity |
| DE4322826A1 (de) | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
| IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
| DE4329503A1 (de) | 1993-09-01 | 1995-03-02 | Galenik Labor Freiburg Gmbh | Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa |
| US5616588A (en) | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
| AU688782B2 (en) | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
| US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| IL111003A0 (en) * | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
| US5516770A (en) | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
| GB9326284D0 (en) | 1993-12-23 | 1994-02-23 | Erba Carlo Spa | Pyrrolydenemethyl-derivatives and process for their preparation |
| WO1995033490A1 (en) | 1994-06-02 | 1995-12-14 | Enzon, Inc. | Method of solubilizing substantially water insoluble materials |
| FR2722984B1 (fr) | 1994-07-26 | 1996-10-18 | Effik Lab | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees |
| SE9403846D0 (sv) * | 1994-11-09 | 1994-11-09 | Univ Ohio State Res Found | Small particle formation |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US5547948A (en) | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
| US5759577A (en) | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
| JPH10513200A (ja) | 1995-02-06 | 1998-12-15 | ナノシステムズ エルエルシー | 可消化オイル又は脂肪酸中の微粒子分散物である化合物の製剤 |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
| US5616595A (en) * | 1995-06-07 | 1997-04-01 | Abbott Laboratories | Process for recovering water insoluble compounds from a fermentation broth |
| MX9709134A (es) * | 1995-06-07 | 1998-03-31 | Conoco Inc | Hilado de fibras de carbono de peces solvatadas. |
| DK0833828T3 (da) | 1995-06-09 | 2003-03-17 | Novartis Ag | Rapamycinderivater |
| IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| US5766623A (en) | 1996-03-25 | 1998-06-16 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Compactable self-sealing drug delivery agents |
| DE19635999A1 (de) | 1996-09-05 | 1998-03-12 | Dystar Textilfarben Gmbh & Co | Farbstoffmischungen von faserreaktiven Azofarbstoffen und ihre Verwendung zum Färben von hydroxy- und/oder carbonamidgruppenhaltigem Fasermaterial |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5985325A (en) | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
-
1996
- 1996-07-11 BE BE9600631A patent/BE1009856A5/fr active
- 1996-07-11 FR FR9608705A patent/FR2736550B1/fr not_active Expired - Lifetime
- 1996-07-12 EP EP96925741A patent/EP0839028B1/en not_active Expired - Lifetime
- 1996-07-12 SI SI9630730T patent/SI1281400T1/sl unknown
- 1996-07-12 SK SK44-98A patent/SK283571B6/sk not_active IP Right Cessation
- 1996-07-12 KR KR10-1998-0700244A patent/KR100352943B1/ko not_active IP Right Cessation
- 1996-07-12 CA CA002426956A patent/CA2426956C/en not_active Expired - Fee Related
- 1996-07-12 SI SI9630671T patent/SI0839028T1/xx unknown
- 1996-07-12 IL IL144684A patent/IL144684A/en not_active IP Right Cessation
- 1996-07-12 AU AU66152/96A patent/AU706174B2/en not_active Expired
- 1996-07-12 NZ NZ313633A patent/NZ313633A/xx not_active IP Right Cessation
- 1996-07-12 JP JP9506264A patent/JPH11509223A/ja not_active Withdrawn
- 1996-07-12 DE DE69635499T patent/DE69635499T2/de not_active Expired - Fee Related
- 1996-07-12 US US08/981,952 patent/US6004973A/en not_active Expired - Lifetime
- 1996-07-12 EP EP02023033A patent/EP1281400B1/en not_active Expired - Lifetime
- 1996-07-12 IT IT96RM000501A patent/IT1284871B1/it active IP Right Grant
- 1996-07-12 DE DE69631422T patent/DE69631422T2/de not_active Expired - Lifetime
- 1996-07-12 ES ES02023033T patent/ES2250566T3/es not_active Expired - Lifetime
- 1996-07-12 AT AT02023033T patent/ATE310519T1/de not_active IP Right Cessation
- 1996-07-12 IL IL12290596A patent/IL122905A/xx active Protection Beyond IP Right Term
- 1996-07-12 PT PT96925741T patent/PT839028E/pt unknown
- 1996-07-12 CA CA002225960A patent/CA2225960C/en not_active Expired - Lifetime
- 1996-07-12 HU HU9900391A patent/HU226774B1/hu unknown
- 1996-07-12 RU RU98102855/14A patent/RU2159107C2/ru active Protection Beyond IP Right Term
- 1996-07-12 ES ES96925741T patent/ES2215195T3/es not_active Expired - Lifetime
- 1996-07-12 SK SK186-2002A patent/SK283572B6/sk not_active IP Right Cessation
- 1996-07-12 AT AT96925741T patent/ATE258429T1/de active
- 1996-07-12 DK DK02023033T patent/DK1281400T3/da active
- 1996-07-12 TR TR1998/00045T patent/TR199800045T1/xx unknown
- 1996-07-12 CN CN96196788A patent/CN1080120C/zh not_active Expired - Lifetime
- 1996-07-12 CZ CZ199891A patent/CZ291305B6/cs not_active IP Right Cessation
- 1996-07-12 PL PL324502A patent/PL191933B1/pl unknown
- 1996-07-12 WO PCT/EP1996/003066 patent/WO1997003654A2/en active IP Right Grant
- 1996-07-12 BR BR9609537A patent/BR9609537A/pt not_active Application Discontinuation
- 1996-07-12 DK DK96925741T patent/DK0839028T3/da active
-
1998
- 1998-01-08 NO NO19980081A patent/NO314924B1/no not_active IP Right Cessation
-
1999
- 1999-03-29 HK HK99101280A patent/HK1016081A1/xx not_active IP Right Cessation
- 1999-08-13 US US09/374,899 patent/US6197781B1/en not_active Expired - Lifetime
-
2000
- 2000-01-13 UY UY25896A patent/UY25896A1/es not_active Application Discontinuation
-
2002
- 2002-07-12 US US10/194,826 patent/US6599535B2/en not_active Expired - Fee Related
- 2002-10-23 NO NO20025089A patent/NO317702B1/no not_active IP Right Cessation
-
2003
- 2003-06-04 US US10/454,017 patent/US6956043B2/en not_active Expired - Fee Related
- 2003-07-11 JP JP2003273402A patent/JP2004002457A/ja not_active Withdrawn
- 2003-12-22 CL CL200302715A patent/CL2003002715A1/es unknown
-
2005
- 2005-07-26 CY CY0500043A patent/CY2603B2/xx unknown
- 2005-10-21 US US11/255,359 patent/US20060115533A1/en not_active Abandoned
-
2007
- 2007-02-09 CY CY0700003A patent/CY2571B1/xx unknown
-
2008
- 2008-02-29 JP JP2008049742A patent/JP5522901B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-22 JP JP2011281577A patent/JP2012082217A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0839028B1 (en) | Solid dispersions of rapamycin | |
| EP1432408B1 (en) | Pharmaceutical compositions comprising colloidal silicon dioxide | |
| WO2013022201A1 (en) | Process of preparing a stabilized and solubilized formulation of sirolimus derivatives | |
| US20130039951A1 (en) | Process Of Preparing A Stabilized And Solubilized Formulation Of Sirolimus Derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |